2 citations
,
June 2014 in “مجلة مركز بحوث التقنيات الاحيائية” Five different TPO gene mutations were found in PCOS patients with thyroid hormone issues.
12 citations
,
June 2016 in “Clinical and experimental dermatology” A new genetic mutation in the TRPV3 gene causes Olmsted-like syndrome in a Mongolian family.
15 citations
,
June 2019 in “Biochemical Journal” A new genetic disorder caused by an ODC1 mutation can be treated with DFMO.
4 citations
,
August 2023 in “Varna Medical Forum” TECAR therapy helps with pain relief, reduces inflammation, relaxes muscles, heals tissues, and is safe and effective for many conditions.
November 2024 in “Advances in Pharmacology and Pharmacy” A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.
July 2025 in “New Phytologist” MLO proteins help regulate calcium and ROS levels, promoting root hair growth in Arabidopsis.
January 2023 in “Al-Azhar International Medical Journal /Al-Azhar International Medical Journal” Acne patients have higher mTOR gene expression.
3 citations
,
February 2023 in “BMJ Case Reports” OnabotulinumtoxinA treatment improved hair-pulling disorder and hair regrowth in a woman with chronic migraines.
288 citations
,
January 2001 in “Journal of Biological Chemistry” Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
July 2024 in “JAAD Case Reports” Corticosteroid injections for hair loss may cause eye problems, so caution is needed.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
April 2025 in “Experimental Eye Research” The Oat mouse model shows mild retinal degeneration, useful for testing treatments.
March 2024 in “Research Square (Research Square)” The TT genotype of a specific SNP in sheep is linked to better wool quality.
June 2022 in “Pakistan Journal of Medical and Health Sciences” Topical clobetasol propionate 0.05% ointment is more effective in promoting hair regrowth in patients with alopecia areata than topical tacrolimus 0.1% ointment.
2 citations
,
December 2019 in “Al-ʻulūm al-ṣaydalāniyyaẗ” The CTLA-4 gene change studied does not affect Polycystic Ovarian Syndrome in the women tested.
10 citations
,
January 2011 in “Journal of biomedical optics” OCT is a reliable, noninvasive way to measure hair thickness.
65 citations
,
March 2004 in “Journal of Clinical Investigation” Inhibiting ornithine decarboxylase may help prevent certain skin cancers.
February 2023 in “Reactions Weekly” Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.
4 citations
,
January 2009 in “International journal of trichology” Minoxidil topical foam is a better, less irritating treatment for hair loss.
113 citations
,
May 2002 in “PubMed” Overexpressing COX-2 in mice skin reduces skin tumor development.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
51 citations
,
December 2006 in “Mammalian Genome”
2 citations
,
January 1990 in “Leukemia & Lymphoma” The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.
2 citations
,
November 2017 in “Gynecological Endocrinology” The enzyme myo-inositol oxygenase is not linked to the cause of polycystic ovarian syndrome.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
January 2019 in “Florida International University Digital Commons (Florida International University)” TOF-SIMS improved chemical mapping in cells, confirming gunshot residue, tracking anti-tumor drugs, and identifying molecules in mosquitoes and wounds.
October 2019 in “Al Mustansiriyah Journal of Pharmaceutical Sciences” The CTLA-4 gene polymorphism does not affect polycystic ovarian syndrome.
306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.